How Blood Based Biomarkers are Reshaping the Alzheimer's Testing Pathway

Tracking # 20-1339601

Price not reported

There are no ratings for this course

Learn more

Educator ASSOCIATION FOR DIAGNOSTICS & LABORATORY MEDICINE

CE Broker Reporting Reported automatically

Method Broadcasted Interactive Event

Dates Contact provider

Course overview

Discover the future of Alzheimer's disease testing in our upcoming webinar, where we'll explore the transformative role of blood biomarkers. Growing demand for early disease stage diagnosis and regulatory approvals of Alzheimer's disease blood biomarker tests can drive their accelerated integration into clinical laboratory routine workflows. This insightful webinar is designed to provide attendees with an understanding of clinical and practical considerations, ultimately empowering them to make more informed decisions. Learn from experts about the clinical value and applications of these biomarkers, which could position your laboratory at the forefront of Alzheimer's disease testing.

Subject areas

This course counts toward the state boards and subject areas below.

American Board of Clinical Chemistry

Clinical Chemistry Diplomate

1h Category 1

Molecular Diagnostics Diplomate

1h Category 1

Toxicological Chemistry Diplomate

1h Category 1

Florida Board of Clinical Laboratory Personnel

Clinical Laboratory Director

1h General

Clinical Laboratory Supervisor

1h General

Clinical Laboratory Technician

1h General

Clinical Laboratory Technologist

1h General

Public Health Director

1h General

Public Health Supervisor

1h General

Public Health Technologist

1h General

Disclosure statements

The Association for Diagnostics & Laboratory Medicine (formerly AACC) is dedicated to ensuring balance, independence, objectivity, and scientific rigor in all educational activities. All participating planning committee members and faculty are required to disclose to the program audience any financial relationships related to the subject matter of this program. Disclosure information is reviewed in advance in order to manage and resolve any possible conflicts of interest. The intent of this disclosure is to provide participants with information on which they can make their own judgments.

The following faculty reported financial relationships:

Lawren VandeVrede, MD, PhD
Honorarium: Peerview CME, Haymarket
Consulting Fees: Roche, Biogen, Siemens, Guidepoint Global Consulting
Grant and/or Research Support: LabCorp, Quanterix, C2N
Committee and/or Advisory Board: Biogen, Siemens

The following faculty reported no financial relationships:

Nicholas Ashton, PhD